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ABSTRACT
Introduction Low back pain (LBP) is among the top three 
most common diseases worldwide, resulting in a life with 
pain- related disability. To date, no study has assessed the 
efficacy of metamizole (dipyrone), a non- opioid analgesic 
and antipyretic prodrug compared with the conventional 
non- steroidal anti- inflammatory drug ibuprofen, in patients 
with an acute LBP episode. Further, it is unclear, whether 
a short educational intervention is superior to usual care 
alone.
Objectives The objective of this study is to assess first, 
whether metamizole is non- inferior to ibuprofen in a new 
episode of acute or subacute LBP. Second, we aim to 
assess whether a short educational intervention including 
evidence- based patient information on the nature of LBP is 
superior to usual care alone.
Methods and analysis An investigator- initiated 
multicentre, randomised, double blind trial using a factorial 
design will be performed. A total of 120 participants with 
a new episode of LBP will be recruited from GP practices, 
outpatient clinics and from emergency departments, and 
randomised into four different treatment groups: ibuprofen 
alone, ibuprofen and short intervention, metamizole alone, 
metamizole and short intervention. The primary endpoint 
for the medical treatment will be change in pain assessed 
on an 11- point Numeric Rating Scale after 14 days. The 
primary outcome for the short intervention will be change 
in the Core Outcome Measures Index assessed after 42 
days.
Ethics, dissemination and funding This study 
has been approved by the responsible Ethics 
Board (Ethikkommission Bern/2018- 01986) 
and the Swiss Agency for Therapeutic Products 
(Swissmedic/2019DR4002). Results will be published in 
open access policy peer- reviewed journals. The study is 
funded by the Swiss National Science Foundation (grant 
number 32 003B- 179346).
Trial registration number NCT04111315
INTRODUCTION
Low back pain (LBP) is among the top three 
most common diseases worldwide, resulting 
in a life with pain- related disability.1 In 
patients with persistent LBP over 3 months, 
the risk for chronic pain increases sharply2 
and effective interventions should aim to 
prevent pain persistence without overtreat-
ment.3 Therefore, treatment guidelines 
recommend the use of pain medication and 
to keep patients physically active during an 
acute LBP episode.4 5 Despite the frequency 
of LBP, only few high- quality studies assessed 
the efficacy of pain medication. Systematic 
reviews of randomised clinical trials found 
Strengths and limitations of this study
 ► This is the first randomised double- blind study 
assessing the analgesic effect of metamizole 
compared with the conventional non- steroidal anti- 
inflammatory drug ibuprofen in patients with acute 
or subacute low back pain (LBP) presenting to the 
GP or emergency department.
 ► In addition, this study will assess whether a short 
educational intervention is more effective in patients 
with LBP compared with usual care.
 ► Due to the high proportion of patients who will not 
require extended pain treatment during an acute 
LBP episode, the trial design mirrors current clinical 
practice.
 ► The primary endpoint pain intensity will be assessed 
after 14 days. The primary outcome for the short in-
tervention will be assessed after 42 days.
 ► While patients, physicians and researchers are 
blinded to the pharmacological treatment, blinding 
is not feasible for the short educational intervention.
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opioids to be no more effective than non- opioid medica-
tion in LBP6 7 but opioids were associated with potentially 
severe side effects.4 7 8 Therefore, non- opioid pain medi-
cations that are safe and effective are urgently needed to 
control pain.
Current treatment guidelines recommend non- 
steroidal anti- inflammatory drugs (NSAIDs) for acute 
pain control.4 9 However, adverse events (AEs) including 
kidney injury and gastrointestinal bleeding limit their use 
in many patients. Metamizole (dipyrone) is a non- opioid 
analgesic and antipyretic with a favourable gastrointes-
tinal and renal safety profile.10 For example, metamizole 
use was associated with a lower risk for gastrointestinal 
bleeding compared with NSAIDs and for hepatotoxicity 
compared with paracetamol.11 Although metamizole has 
been withdrawn from the market or never approved in 
many countries including the USA, Canada and UK,12 
it is frequently used in many other countries such as 
Germany,13 Spain,12 Switzerland,14 some Eastern Euro-
pean and South American countries.12 15 Despite its 
increasing use in many European countries,14 16 the role 
of metamizole for the treatment of LBP is unclear and has 
so far not been systematically studied. This may be due to 
an ongoing controversy regarding the risk of metamizole- 
associated agranulocytosis.12 15 Due to the rare occur-
rence, incidence rates have been based on case–control 
studies and pharmacovigilance data. The incidence of 
the metamizole- induced agranulocytosis was estimated 
between 0.5 and 3.5 cases per 1 million metamizole users 
over 1 week per year.17–28 Even though the overall risk of 
agranulocytosis is higher compared with other analgesics, 
it remains a rare event occurring only in a small propor-
tion of susceptible patients17–25 27–29 and the overall safety 
profile of metamizole is still favourable compared with 
NSAIDs or opioids.30
Many patients have reservations against regular intake 
of pain medication and, contrary to guideline recommen-
dations, limit physical activity to keep pain manageable 
without medication.31 Patient education encouraging 
physical activity may help to improve pain control and 
function. For example, a Cochrane review found that 
2.5- hour educational sessions were more effective than 
no intervention on the return- to- work rate in patients 
with acute/subacute LBP.32 Such time- intensive inter-
ventions may not be necessary in all patients and are not 
feasible in a busy primary care practice. Short educational 
interventions would be more practical, however, to date, 
it is unclear whether they also have a positive effect on 
outcome in patients with a new LBP episode.
Objectives
The first objective of this study is to assess whether 
metamizole is non- inferior to ibuprofen in patients with a 
new episode of acute or subacute LBP. The second objec-
tive is to assess whether a short educational intervention, 
including evidence- based patient information on the 
nature of LBP, is superior to usual care alone. Thus, this 
randomised trial will provide new knowledge regarding 
the efficacy of non- opioid pain medications in LBP. In 
addition, if the short educational intervention proves to 
be beneficial compared with usual care, the trial will help 
to improve care for patients with a new LBP episode.
METHODS AND ANALYSIS
The methods reporting of this randomised trial will follow 
the recommendations of the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 
statement.33
Design: multicentre, randomised, double-blind trial using a 
factorial design
The Efficacy of Metamizole versus Ibuprofen and a Short 
Educational Intervention versus Standard Care in Acute 
and Subacute Low Back Pain (EMISI) study is a multi-
centre, randomised, double- blind trial using a factorial 
design to investigate whether metamizole is non- inferior 
to ibuprofen in patients with a new- onset LBP episode. 
Patients, physicians and researchers will be blinded to 
the allocation of the study medication. A non- inferiority 
design was chosen as metamizole seems to be equally 
effective as ibuprofen in clinical practice. Furthermore, 
the study will assess whether a short educational inter-
vention including evidence- based patient information is 
superior to usual care. Blinding patients about the short 
intervention is not possible but blinding is upheld in 
GPs and researchers (double blind). The primary eval-
uation of outcomes (see the Outcome measure section 
for details) will be performed at day 14 (comparison of 
metamizole to ibuprofen) and at day 42 (comparison of 
educational short intervention to usual care).
Eligibility criteria
Subjects fulfilling all of the following inclusion criteria 
are eligible for the study:
 ► Age 18 years or older.
 ► Seeking care for new onset of non- specific or specific 
LBP (pain duration of less than 12 weeks LBP prior to 
the baseline visit).
 ► The GP plans to prescribe a non- opioid pain medica-
tion for pain control.
 ► Informed consent documented by signature.
Exclusion criteria are:
 ► Chronic use of opioids.
 ► Presence of red flags (serious neurological deficit 
requiring surgery, infection, vertebral fracture).
 ► Known intolerance to the study medication (ie, 
previous acute allergic reaction to NSAIDs or 
metamizole).
 ► Active malignancy and/or history of a (previous) 
haematological disorder (history of agranulocytosis).
 ► History of anaemia (haemoglobin of  <10.0 g/L), 
neutropaenia (leucocyte count of  <3.0 x 109/L), 
thrombocytopaenia (<100 G/L).
 ► Known contraindications against the study medi-
cations: previous gastrointestinal ulcer/bleeding, 
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inflammatory bowel disease, heart failure (New York 
Heart Association (NYHA) Functional Classification 
III–IV), liver failure (liver cirrhosis, ascites), renal 
insufficiency (estimated glomerular filtration rate 
(eGFR)  <60 mL/min/1.73 m2) or previous acute 
kidney injury (AKI stage 2 according to the Kidney 
Disease: Improving Global Outcomes (KDIGO) 
definition).
 ► Immune deficiency or under immunosuppressant 
treatment.
 ► Known or suspected non- compliance, drug or alcohol 
abuse.
 ► Participation in another study within 30 days 
preceding randomisation and during the present 
study or previous enrolment into the current study.
 ► Enrolment of the investigator, his/her family 
members, employees and other dependent persons.
 ► Pregnancy: In women of childbearing age, a negative 
pregnancy test (urine or blood test as available in the 
primary care practice) before inclusion is required. 
Women who are not willing to use safe contraception 
(condom or birth control pill) during the trial, inten-
tion to become pregnant during the trial, pregnancy 
or breast feeding.
Study setting
The EMISI trial will be coordinated by the central study 
team at the Division of General Internal Medicine, 
University Hospital Bern, Switzerland. Patients will be 
recruited from outpatient clinics, from GP practices, and 
from emergency departments. The overall study dura-
tion of 42 days (6 weeks) was chosen because treatment 
guidelines recommend further assessment of patients for 
multidisciplinary treatment if LBP persists for more than 
6 weeks despite pain medication and the advice to stay 
active. This is an investigator- initiated trial. The funder 
will have no role in the study design, the trial oversight, 
data collection, analysis of the study and publication of 
the results.
Estimated sample size and power
Both interventions are considered for determining the 
sample size for this factorial trial.34 We expect the two 
primary hypotheses to be independent of each other and 
do not expect an interaction between both interventions. 
Therefore, we powered each hypothesis individually, but 
accounted for multiple testing by adjusting the type- I 
error rate by setting the alpha level to 0.025 in each test to 
keep the overall type- I error rate at 0.05. Thus, we aimed 
to include 120 patients to account for a drop- out of 10% 
which will allow to proof non- inferiority of the metam-
izole treatment at a one- sided alpha- level of 2.5% with a 
power of 90%.
The sample size calculation for the comparison of 
metamizole versus ibuprofen was based on a difference 
in the change of pain score in the Numeric Rating Scale 
(NRS; range 0–10, higher score indicates more pain). 
We considered a change of  ≥2 points between the two 
groups as clinically relevant and a change of  ≤1 point 
as negligible.35 36 Therefore, we set the non- inferiority 
margin to −1 score point. Based on a two- sample means 
test and an SD of 1.6,35 we will need 108 patients (54 per 
group) to proof non- inferiority of the metamizole treat-
ment at a one- sided alpha- level of 2.5% with a power of 
90%.
The sample size for the primary outcome compar-
ison short intervention versus usual care (superiority) 
is based on a change in Core Outcome Measures Index 
(COMI; range 0–10, higher score indicates higher level 
of complaint, see primary outcomes) from baseline to 
week 6. We hypothesise that there is a difference between 
the two intervention groups regarding COMI. Mannion 
et al37 reported a minimal clinically important difference 
(MCID) for improvement in the COMI of 2.2 points and 
SD for changes in COMI ranging from 1.7 to 2.5 points. 
We see a difference of 2.2 points between the two groups 
as clinically relevant and assume a SD of 2.2 points. Based 
on a two- sample means test, we will need 54 patients (27 
per group) to detect a difference in the change of the 
COMI at a two- sided alpha- level of 2.5% with a power of 
90%.
Primary outcome
Table 1 provides an overview of measurements according 
to the SPIRIT. The primary outcome for the comparison 
of metamizole versus ibuprofen is the change in pain on 
the NRS (range 0–10 points) from baseline to follow- up 
at day 14 (non- inferiority). Pain intensity will be recorded 
as average pain intensity for the past 24 hours on an NRS 
scale from 0 to 10, scored from 0 (no pain) to 10 (worst 
possible pain). The rational for assessing the effectiveness 
outcome at 14 days was based on the double- blind RCT 
comparing paracetamol to placebo.38
The primary outcome for the comparison of the 
short intervention versus usual care is the change in the 
COMI sum- score (range 0–10) from baseline to 42 days 
follow- up (superiority). The COMI is a short, multidi-
mensional, validated outcome instrument with excellent 
psychometric properties recommended for the moni-
toring of the outcome in patients undergoing treatment 
for LBP.37 The COMI sum score is calculated as described 
in the validation paper.39 40 The pain scales (item 2a and 
2b) are scored 0–10, while the category scales (items 3–7) 
are scored as 0, 2.5, 5.0, 7.5, 10.0. The sum score (0–10) 
for the whole COMI scale is calculated based on the 
following five domains:
 ► Pain domain: higher of the two pain scores (higher of 
2a and 2b) is taken as the score.
 ► Disability domain: the average of the two disability 
items (6 and 7).
 ► Back related function (item 3).
 ► Symptom specific well- being (item 4).
 ► General quality of life (item 5).
The five domain scores are then averaged to give a 
COMI score from 0 to 10.
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Table 1 Summary of study procedures based on Standard Protocol Items: Recommendations for Interventional Trials 
schedule
Enrolment Allocation Short intervention Phone call Clinical visit Phone call Clinical visit or phone call
Time point (days) −5 to 0 0 2 7 14 28 42
Clinical visit 1 1 2 3 or ✆4
Phone call ✆2 ✆3 ✆3







Vital signs x x (x)
Blood analysis x x (x)
Pregnancy test x
Randomisation x
Hand out study 
medication
x
Daily intake of study 
medication
x
Group 1+3: study 
medication only
x x x x x
Group 2+4: study 
medication  +short 
intervention
x x x x x x
Pain diary daily 
including:
 ► Pain
 ► Additional treatments
 ► AE
 ► Daily physical 
activity
x x x x x x
Adherence reminder3 x x
Screening for9:
 ► AE and SAE
 ► Interrupting or 
discontinuing 
treatment
x x x x
Collection of pill bottles 
for pill count
x x
Self- reported measures collected during visits
  Pain questionnaire 
(NRS)
x x x
  COMI x x x
  STarT Back tool x x x
  Quality of life (EQ5- 
D- 5L)
x x x
  Fear avoidance 
(FABQ)
x
  Self- efficacy (FESS) x
  Blinding control x
  Voluntary in- person 
interview on patient 
perspective
x
AE, adverse event; COMI, Core Outcome Measures Index; EQ5- D- 5L, European Quality of Life- 5 Dimensions questionnaire; FABQ, Fear Avoidance 
Questionnaire; FESS, FESS, self- efficacy (Schmerzspezifische Selbstwirksamkeit); NRS, Numeric Rating Scale; SAE, serious adverse event.
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Two additional questions cover the satisfaction with 
treatment outcome. An MCID found to be relevant for 
patients was a reduction in COMI score of  ≥2.2 points.37
Secondary outcome
All outcome measures used in this study were recom-
mended by the NIH Task force and other expert panels 
to study back pain.41 42 Table 1 provides an overview of 
measurements according to the SPIRIT.33
Secondary outcome measures include:
 ► Change in pain on the NRS (range 0–10 points) from 
baseline to follow- up at day 42.
 ► Change in the COMI sum- score (range 0–10) from 
baseline to 14 days follow- up.
 ► The proportion of patients with an MCID in the NRS 
(≥2 points) and COMI (≥2.2 points) at days 14 and 
42.
 ► Time to recovery (recovery defined as the first day 
with an NRS of  <2 points sustained for two consecu-
tive days).
 ► Change in overall pain intensity from baseline to 
follow- up at day 14 and day 42. Overall pain intensity: 
average of ratings for average pain, pain at rest, and 
pain during activity during the last 24 hours.
 ► Area under effect curve (day 0–14) NRS.
 ► AEs.
 ► Time to stopping treatment.
 ► Global effectiveness of the treatment (COMI question 
‘how much did the operation/treatment help your 
back problem?’ 5- point Likert scale from ‘helped a 
lot’ to ‘made things worse’).
 ► Daily physical activity (daily step count).
 ► Use of pain medication and additional rescue 
medication.
 ► Additional treatment (physical therapy, injections).
 ► Return to work (yes/no).
 ► Treatment satisfaction (COMI).
 ► Quality of life as assessed by the 5- level version of the 
European Quality of Life- 5 Dimensions questionnaire 
(EQ- 5D).
 ► Psychological factors (STarT- Back Tool).43
Exploratory variables
Response to pain medications may be influenced by 
individual pharmacokinetic and pharmacodynamics 
factors. Therefore, we will collect blood samples during 
visit 2 (day 14) to assess the following factors that may 
influence the individual response to the pain medica-
tions. First, we will measure plasma concentrations of 
ibuprofen and the four main metamizole metabolites 
(4- MAA, 4- AA, 4- FA, 4- AAA). Pharmacodynamic effects 
of metamizole correlate primarily with concentrations 
of the 4- MAA metabolite,44 thus, direct quantification of 
4- MAA concentrations will add important information for 
the interpretation of the observed effects.45
Second, as individual response to ibuprofen may be 
affected by genetic polymorphisms of cytochrome P450 
(CYP) isoforms 2C8 and 2C9, the study population 
will be characterised in terms of CYP 2C8/9 genotypes 
(CYP2C8 *1 and *3 alleles, CYP2C9 *1, *2, and *3 alleles). 
In subjects with alleles conferring low CYP2C8 and/or 
CYP2C9 activity, reduced ibuprofen clearance of both 
enantiomers has been described, resulting in several- fold 
increased exposure and prolonged half- life compared 
with subjects with wild- type alleles.46 47
Study procedures
Study procedures are summarised in the study flow chart 
(figure 1). Each participating site will receive a supply 
of sequentially coded, blinded and sealed intervention 
packs. All patients presenting with LBP will be screened 
for potential inclusion into the study. After obtaining 
informed consent by the physician, patient information 
will be entered in a web- based clinical data management 
Figure 1 Study flow chart. GP, general practitioner; COMI, Core Outcome Measures Index; NRS, Numeric Rating Scale.
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system (CDMS). After patient registration in the CDMS 
and confirmation of all inclusion and exclusion criteria, 
patients are randomised using sequentially coded and 
blinded intervention packs, thus ensuring concealment 
of allocation. The number of the intervention pack will 
be recorded in the CDMS.
Patients will complete a set of self- reported question-
naires (see table 1 for details) on demographics (age, 
sex, work and civic status), previous history, current medi-
cations, pain related information (NRS, pain drawing), 
disability (COMI, STarT Back tool), quality of life (EQ5- 
D- 5L), the Fear Avoidance Questionnaire,48 self- efficacy 
(Schmerzspezifische Selbstwirksamkeit49). Physicians will 
complete a questionnaire on clinical findings, the clinical 
diagnosis, previous and newly prescribed treatments.
On completion of the baseline evaluation, patients 
may open the intervention pack and start treatment. The 
intervention pack will contain a pill bottle and an enve-
lope with the assignment of the short versus no interven-
tion and a pain diary.
Between the first and the second visit, patients will 
record their pain before intake of study drug, the number 
of study drugs and additional pain medications, and their 
daily physical activity (quantified by daily step counts 
using a commercially available wearable step tracking 
device (Garmin vivofit 4).
To mitigate the risk for AEs, we will collect blood 
samples after the randomisation in all patients. In case 
of a newly detected renal insufficiency (defined as eGFR 
<60 mL/min/1.73 m2), leucopaenia (leucocyte count 
<3.0 G/L), thrombocytopaenia (defined as  <100 G/L) 
and/or anaemia ((haemoglobin  <100 g/L), we will stop 
the study medication.
During the second visit (day 14), patients will return 
the pill bottles and the pain diary to the GPs office where 
they are collected for pill count. The patient will receive 
a new drug pack and pain diary. A blood sample will be 
collected (creatinine, blood count, drug concentrations 
and genotyping), and self- reported questionnaires and a 
clinical assessment will be completed. The GP will record 
the clinical findings and additional pharmacological and 
non- pharmacological treatments.
To improve adherence, study staff will call patients 
between the first and the second visit and between the 
second and the final visit and ask for AEs and addi-
tional pain treatment. As we expect a high proportion 
of patients to have recovered by day 28 (second phone 
call), researchers will then determine whether a clinical 
visit on day 42 is necessary. In case patients have recov-
ered by day 28, patients do not need to attend the clin-
ical visit. Patients will be asked whether they would be 
willing to participate in an in- person interview at the end 
of the study. The aim of the interview is to assess factors 
that were relevant for patients during their LBP treat-
ment. The interview will be recorded (video and audio) 
for qualitative analysis using standard grounded theory 
method according to Philipp Mayring.50
A final assessment will be done on day 42 during a clin-
ical visit in patients who had persisting symptoms on day 
28. Patients will return the pain diary and the pill bottles 
with the remaining pills to the GPs office where they are 
collected for pill count. Data collection includes self- 
reported validated questionnaires. The GP will record 
the clinical findings and additional pharmacological and 
non- pharmacological treatments. A final blood sample 
(serum creatinine and blood count) will only be collected 
if patients are still taking study medication. Patients who 
do not need to attend the clinical visit will receive a final 
identical set of questionnaires by mail and will be asked for 
AE/SAE and additional treatments during a phone call. 
Patients will return the questionnaires together with the 
pain diary and the pill bottles to the central study team. 
To assess the success of blinding, patients will be asked at 
the end of the study what treatment group they believe 
they had been assigned to (metamizole or ibuprofen).
Pharmacological intervention
During the first 4 days, we will compare a fixed- dose 
regimen of metamizole 500mg to 500 mg ibuprofen lysine 
(lysine- 2- (4- isobutylphenyl)- propionate, corresponds to 
292.6 mg ibuprofen acid) three times two capsules per day 
(table 2). Ibuprofen was chosen as a comparator because 
it is a well studied and the most frequently prescribed 
NSAID in Switzerland14 with a similar dosing interval as 
Table 2 Oral doses for study medication—fixed dose and as- needed regimen
Group Study medication Fixed dose regimen (days 0–3)
As- needed regimen (after day 3): recommended reduction of the 
oral intake when LBP decreases
1 Ibuprofen only 500 mg* 2- 2- 2 2- 2- 2 (pain unchanged), 1- 1- 1 (decreased pain; NRS <4 points), 1- 0- 
1, 1- 0- 0
2 Ibuprofen +short 
intervention
500 mg* 2- 2- 2 2- 2- 2 (pain unchanged), 1- 1- 1 (decreased pain; NRS<4 points), 1- 0- 
1, 1- 0- 0
3 Metamizole only 500 mg 2- 2- 2 2- 2- 2 (pain unchanged), 1- 1- 1 (decreased pain; NRS<4 points), 1- 0- 
1, 1- 0- 0
4 Metamizole+short 
intervention
500 mg 2- 2- 2 2- 2- 2 (pain unchanged), 1- 1- 1 (decreased pain; NRS<4 points), 1- 0- 
1, 1- 0- 0
*500 mg ibuprofenum lysinum (lysine- 2- (4- isobutylphenyl)- propionate) corresponds to 292.6 mg ibuprofen acid.
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metamizole. The initial dose of both medications is the 
currently used and recommended dose for the treatment 
of acute pain (common daily dose for metamizole 3000 mg 
(maximum daily dose 4000 mg) and 3000 mg ibuprofen 
lysine (maximum daily dose 4000 mg)). Ibuprofen lysine 
3000 mg corresponds to 1800 mg ibuprofen acid. The 
ibuprofen lysine formulation was chosen to facilitate 
blinding of the study drug, as ibuprofen lysine 500 mg 
was the only ibuprofen formulation available on the Swiss 
market, which could be prescribed with identical number 
of capsules and at identical intervals as metamizole. The 
lysine salt of ibuprofen shows better solubility and faster 
absorption compared with the acid form.44 51 However, 
overall extent of absorption and analgesic effect in an 
acute pain model did not differ from the acid form.52
In LBP, current clinical practice is to prescribe an initial 
fixed dose regimen followed by an as- needed regimen that 
allows patients to adjust the daily dose depending on their 
pain intensity. To mirror clinical practice, patients will be 
allowed after the first 4 days to decrease the intake of the 
study medication according to a dose reduction schedule 
(as needed phase). From day 4 until recovery, patients 
may reduce the daily pain medication intake once their 
pain has decreased to less than four points on the NRS 
(range 0–10 points) every 2 days. The treatment duration 
will thus depend on the duration of pain. Patients are 
considered to have recovered when their pain is below 
2 (NRS 0–10) on two consecutive days after they have 
stopped intake of pain medication (end of treatment).
Non-pharmacological educational short intervention
Patients assigned to the short intervention will receive 
together with the pain medication a short leaflet focusing 
on the nature of non- specific LBP and the importance of 
staying active. A second leaflet contains exercises to alle-
viate LBP. The content of the short information leaflet is 
based on the The Back Book.53 Further, all patients assigned 
to the short intervention will receive a 10 min standardised 
telephone intervention delivered by a trained member of 
the study team during the first 4 treatment days to help 
patients understand the non- dangerous nature of LBP, 
and to explain the purpose of pain medication to facili-
tate movement. In addition, patients will be encouraged 
to stay active and to perform the exercises as proposed in 
the exercise leaflet.
Concomitant interventions
In a double- blind randomized clinical trial (RCT) 
comparing paracetamol to placebo for LBP in the primary 
care setting, rescue medications were infrequently used.38 
Therefore, physicians will be allowed to prescribe addi-
tional rescue medications recommended by treatment 
guidelines at their discretion. Additional medication 
use is recorded in the pain diary, during the phone calls 
and the clinical visits. Further, information on any use of 
physical therapy, massage or other treatments is collected 
during the follow- up visits at days 14 and 42. Although GPs 
will be instructed to withhold physical therapy until day 
14 (ie, the primary effectiveness endpoint for metamizole 
vs ibuprofen) if the clinical situation allows, additional 
care including physical therapy and relaxation strategies 
recommended by guidelines will be at the discretion of 
the treating GP. GPs will record any additional prescrip-
tion of addiational care. Concomitant treatments will be 
treated as covariates to assess their potential impact on 
overall efficacy (performance bias).
Randomisation and allocation procedures
The allocation sequence (randomisation list) will be 
generated by an independent data manager at the clin-
ical trial unit (CTU) Bern who is not otherwise involved 
in the trial. Randomisation will be blocked and stratified 
according to study sites. To ensure concealment of alloca-
tion, block size will not be communicated. After patient 
data are registered in the CDMS, eligibility is confirmed 
and signed informed consent is obtained, patients will 
be assigned to the next sequentially coded intervention 
pack that is available at the recruiting site. Patients are 
randomised 1:1:1:1 into one of four groups: Metam-
izole  +educational intervention versus metamizole 
+standard care versus ibuprofen  +educational interven-
tion versus ibuprofen  +standard care. The intervention 
packs will contain a pill bottle and an envelope with the 
assignment of the short versus no intervention. The inter-
vention packs will be prepared according to the rando-
misation list by an independent hospital pharmacist not 
involved in the study.
Blinding
Staff at the hospital pharmacy not involved in patient 
recruitment or other trial activities will fill the gelatin 
capsules with the study medication and label the pill 
bottles according to a standard operating procedure and 
based on the randomisation list provided by the CTU 
Bern. The study medication will be delivered in identi-
cally labelled sealed pill bottles containing capsules of 
identical appearance. The randomisation list will be kept 
electronically at the CTU Bern in a password- protected 
file. Study personnel and physicians involved in patient 
recruitment, treatment and outcome assessment will have 
no access to the list.
Due to the nature of the short educational intervention, 
no blinding of patients receiving an information leaflet 
and a telephone call is possible. Therefore, contamina-
tion and performance bias are important to consider. 
The envelope including the leaflet will be sealed and the 
patients will be instructed to open de envelope outside 
the GPs office. GPs will not be informed about the group 
assignment and the content and aim of the educational 
intervention. Patients assigned to the educational inter-
vention will receive a telephone call according to a 
predefined script by a member of the study team other-
wise not involved in patient recruitment, outcome assess-
ment and data analysis. To minimise the risk of detection 
bias, the study outcomes are collected in pain diaries and 
self- reported questionnaires (NRS at day 14, COMI at day 
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42). Study personnel that will contact patients by phone 
for reminders and to collect information on AEs will be 
blinded to the group assignment. To assess differences 
in additional treatments (performance bias), patients 
and GPs will record additional treatments other than the 
study medication and the educational information (eg, 
additional medication use, physical therapy, injections).
The statistician responsible for the final analysis will 
also have no access to the list until the primary analysis of 
the trial is finished. Data analysis will be done according 
to a prespecified analysis plan before the randomisation 
code will be broken. Patients, physicians and data analysts 
will be blinded with regard to the allocation to the study 
medication until after the primary analysis. To assess the 
success of blinding, we will ask patients at the end of the 
study into which group they belief they had been assigned 
to. Data on all recruited patients will be collected and 
regularly monitored.
Statistical analysis plan
The statistical analysis will be performed in compliance 
with the International Conference on Harmonisation’s 
Good Clinical Practice guidelines and the report will be 
developed in line with the Consolidated Standards of 
Reporting Trials statement.
To assess the efficacy for the two primary outcomes, we 
will use two analysis sets (see figure 1). The full analysis set 
(FAS) includes all randomised patients for the intention- 
to- treat (ITT) analysis, that is, all patients will be analysed 
in the group they were assigned to. The per- protocol 
(PP) set is based on the FAS, excluding patients with 
major protocol violations, patients who were excluded 
due to the predefined stop criteria, patients withdrawing 
from the trial within 3 days of treatment start, patients 
undergoing surgery and patients that did not receive the 
randomised treatment or intervention.
We will present patient and procedural characteris-
tics using descriptive statistics (mean and SD or median 
and IQR for continuous variables and frequency and 
percentage for categorical variables).
To compare the efficacy of metamizole and ibuprofen 
(non- inferiority), we use an ITT (FAS set) and a PP anal-
ysis (PP set) for the primary outcome (NRS change from 
baseline to follow- up at 14 days). Both analyses need to 
meet non- inferiority in order to claim success. The differ-
ence in the change in NRS between the two groups will be 
calculated from a linear model, adjusted for the baseline 
NRS value and the type of intervention (short interven-
tion vs standard care). If the lower one- sided 97.5% confi-
dence limit of the difference lies above the non- inferiority 
margin of −1, non- inferiority will be claimed. If we can 
demonstrate non- inferiority, we will additionally test for 
superiority at a two- sided significance level of 2.5%. Since 
testing is nested (ie, hierarchical), this procedure has no 
implication on the overall type- I error rate.
To compare the primary outcome between the short 
educational intervention to usual care (superiority), we 
use ITT analysis (COMI change from baseline to day 42). 
The difference in the change in COMI between the two 
groups will be calculated and tested at a two- sided signifi-
cance level of 2.5% using a linear model, adjusted for the 
baseline COMI and the type of drug treatment. Differ-
ences will be presented with a two- sided 97.5% CI and the 
regular 95% CI.
We will assess both primary outcomes for interaction. 
We will introduce an interaction term between the treat-
ment indicator and the intervention indicator to test 
whether in (A) the effect of the metamizole treatment 
on the change in NRS at day 14 is different in patients 
that receive the short intervention compared with the 
standard care group and in (B) whether the effect of the 
short intervention on the change in COMI at day 42 is 
different in patients that receive metamizole compared 
with patients that receive ibuprofen.
Secondary continuous outcomes will be analysed as 
the primary outcomes. Besides the indicator for the drug 
treatment or intervention, models will be adjusted for the 
baseline value if available. Secondary binary outcomes 
will be analysed using logistic regression models adjusted 
for the indicator for the drug treatment or intervention, 
as applicable. Time- to- event outcomes will be analysed 
using Cox regression adjusted for the indicator for the 
drug treatment or intervention, as applicable. For all 
secondary effect measures, we will display regular two- 
sided 95% CI and accompanying p values.
Further, we will perform additional PP analyses for the 
primary outcome of the comparison between the two 
intervention arms as well as for all secondary outcomes. 
If outcomes are missing, we will employ multiple imputa-
tion in the primary analysis and additionally perform an 
available case analysis disregarding missing data. Contin-
uous outcomes that are measured several times during 
follow- up will additionally be evaluated in a repeated 
measures mixed- effects linear model, additionally intro-
ducing a random intercept for patients into the model.
Exploratory analysis will be conducted with regards to 
predictors for treatment responses. We will explore the 
association between clinical predictors (eg, depression, 
fear avoidance beliefs, social factors), drug levels, or 
genetic mutations and the treatment response in linear 
models. We will perform subgroup analyses according to 
gender, genetic phenotypes and drug levels.
Safety outcomes will be reported as proportion and 
95% CI separately for the two drug treatment groups 
using the safety population (ie, all patients that have 
received at least one dose of the study drug and at least 
one safety- related visit or observation) set.
Patients with missing outcome data will be imputed 
using multiple imputation.
Safety
Protocol violations should not lead to treatment discon-
tinuation unless they indicate a significant risk to patient 
safety.
Patients may be withdrawn from the study treatment for 
the following reasons:
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 ► Haematological disorders including leucopaenia 
(defined as leucocyte count  <3.0 G/L; thrombocyto-
paenia (defined as  <100 G/L) and anaemia (decrease 
in haemoglobin  ≥20 g/L or  <100 g/L).
 ► Potential evidence for a haematological disease (patho-
logical blood smear needing further evaluation).
 ► Decreased kidney function (defined as an estimated 
creatinine clearance using the MDRD formula 
of  <50 mL/min/1.73 m2) or AKI stage 1 or higher 
(defined according to the KDIGO definition: ≥1.5 
times creatinine increase compared with baseline 
value or  ≥26.5 µmol/L creatinine increase).
 ► Development of toxicity which, in the investigators or 
GPs judgement, precludes further use of one of the 
study drugs.
 ► Patients lost to follow- up or non- compliance.
We will comply with all regulations concerning safety 
measures in clinical trials as set forth by the Swiss Agency 
for Therapeutic Products (Swissmedic). The investigators 
will report any serious AEs occurring during clinical trials, 
independent of direct causal relationship with the treat-
ment, within 24 hours. In case of a suspected unexpected 
serious adverse reaction, Swissmedic will be notified 
by the sponsor–investigator within the legal timelines. 
Unblinding will be permissible in case the information 
is required to ensure the patients safety in case of an AE.
All AEs are reviewed by a safety committee and graded 
according to the National Health Service (NIH) Common 
Terminology Criteria for Adverse Events (CTCAE V.5.0).54
Patient and public involvement
In this study, we use information material developed by 
patient advocacy groups. The results of this study will 
be communicated to the patients and physicians partici-
pating in the trial. The results will also be communicated 
to patients’ advocacy groups and may help to improve the 
information material. Further, we will assess the impact of 
the study on patients and factors that may be facilitators 
or barriers to improve pain and pain management in LBP 
during in- person interviews.
Clinical implications
During an LBP episode treatment guideline recommend 
to alleviate pain using pain medication and to stay physi-
cally active. To alleviate pain, NSAIDs are frequently used. 
However, the use of NSAIDs may be limited because of 
common adverse effects. Metamizole has a favourable 
adverse effects profile and may be used as an alternative. 
However, there is a lack of data on its effectiveness and 
safety for the treatment of LBP. This is the first study that 
systematically investigates the efficacy of metamizole in 
LBP patients undergoing treatment over the course of 
several weeks. Therefore, this study will provide evidence 
to support or discourage the use of metamizole in LBP. 
The findings of this study will be especially relevant 
for those patients where NSAIDs should not be used. 
Moreover, this trial is expected to provide evidence for 
a highly needed non- opioid treatment alternative in 
musculoskeletal pain. In particular, because the use of 
opioids has been shown to be no more effective than non- 
opioid medication55 and is associated with potentially 
severe AEs.
Non- pharmacological educational measures may 
potentiate the effect of the pain medication in acute LBP 
by addressing misbeliefs and avoiding disuse. Despite 
good evidence that staying active during an acute LBP 
episode is more effective than bed rest,56 more than 
50% of the Swiss population report avoiding movements 
and increasing rest during an LBP episode.57 The inter-
action between patient and doctor early on influences 
the recovery of patients and many patients may benefit 
from a short educational intervention that is easy to be 
implemented even in a busy GP practice in addition to 
pain medication. This is the first study that investigates 
the impact of a short educational intervention in addi-
tion to pain medication on the recovery and medication 
adherence in patients with acute and subacute LBP. Even 
a small individual effect may have a large impact on the 
overall societal burden of LBP. Our work will inspire novel 
approaches on how to improve adherence to medication 
and behavioural changes.
Ethics and dissemination
The trial will be performed in compliance with the 
Declaration of Helsinki and its amendments, and has 
been approved by the responsible Ethics Board (Ethik-
kommission Bern/2018- 01986) and the Swiss Agency 
for Therapeutic Products (Swissmedic/2019DR4002). 
Important protocol modifications will be communicated 
to the Ethics Board and participating study sites. Poten-
tial participants must provide written informed consent 
before entering the study. Subjects can leave the study 
at any time for any reason without any negative conse-
quences for their further treatment. When a patient ends 
the treatment phase of the study prematurely, we will 
record the date and reason for early treatment discon-
tinuation. If possible, the end of treatment evaluations 
will be collected before the patient is started on any other 
therapeutic intervention. Insurance coverage will be 
provided for all study participants by the study sponsor.
The results of the main trial and each of the secondary 
outcomes will be submitted for publication in open access 
peer- reviewed journals. Results will be disseminated to 
all participating centres and participants expressing 
interest. The EMISI study group is an independent 
academic research group, which will not employ profes-
sional writers. The EMISI study group will comply with 
the open access regulation of the Swiss National Science 
Foundation.
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